Growth factors in pancreatic health and disease

Baláž, Peter; Frieß, Helmut; Büchler, Markus W.

doi:10.1159/000055833

Cited by 14 publications

(9 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Synthetic pancreatic supplements may offset this and should be administered from an early stage to enhance gut absorptive capacity. 1,[18][19][20][21][22][23][24][25] Most authors recommend using somatostatin analogues (Octretoide) although there is no direct evidence to suggest that octreotide helps a fistula to close that would not have otherwise done so. It may, however, expedite closure and at least limits protein and electrolyte losses during fistula management.…”

Section: Discussionmentioning

confidence: 99%

Pleuropancreatic Fistulae: Specialist Center Management

Khan

Ching

Morris‐Stiff

et al. 2009

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Pleuropancreatic Fistulae: Specialist Center Management

Khan

Ching

Morris‐Stiff

et al. 2009

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

show abstract

“…Although not grossly vascular, these cancers exhibit foci of micro‐angiogenesis and overexpress the paramount pro‐angiogenic factor vascular endothelial growth factor (VEGF), and also additional mitogenic growth factors that are likewise angiogenic. ( 1–4 )…”

mentioning

confidence: 99%

Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results

et al. 2010

View full text Add to dashboard Cite

Circulating endothelial cells (CEC) and bone marrow‐derived endothelial progenitors (ECP) play important roles in tumor growth and have been proposed as non‐invasive markers of angiogenesis. However, CEC and ECP levels have not been investigated in pancreatic carcinoma patients. Using four‐color flow cytometry procedures, we evaluated the count of resting (rCEC) and activated (aCEC) endothelial cells and ECP in the peripheral blood of pancreatic carcinoma patients before and after chemotherapy, consisting of gemcitabine (GEM) alone or in combination with oxaliplatin (OX), or with 5‐fluorouracil (5‐FU). We also correlated CEC and ECP levels with plasma levels of relevant angiogenic factors, such as vascular endothelial growth factor (VEGF)‐A, VEGF‐D, angiopoietin (Angio)‐1, and chemokine C‐X‐C motif ligand (CXCL)12, measured by ELISA, and with clinical features of pancreatic cancer. The aCEC, rCEC, ECP, and VEGF‐A plasma levels were significantly higher in locally‐advanced and metastatic patients than controls. Both ECP and VEGF‐A levels correlated positively with disease stage and inversely with patient’s overall survival. Measurements after the treatment course showed that VEGF‐A plasma concentrations and ECP counts had decreased significantly. In particular, VEGF‐A and rCEC were significantly down after treatment with GEM alone or in combination with OX. No significant differences in terms of circulating angiogenic factor or endothelial cell subtype levels were found between responders (patients entering partial remission or with stable disease) and non‐responders (patients with progressive disease). The study provides insights into angiogenesis mechanisms in pancreatic carcinoma, for which anti‐angiogenic targeting of VEGF‐A and ECP could be of interest. (Cancer Sci 2010; 101: 2448–2454)

show abstract

“…This leads to cellular responses that, through activation of specific gene expression, influence cell differentiation and proliferation. These factors exert their effects through both autocrine and paracrine mechanisms, and are involved in fibrogenesis, carcinogenesis, angiogenesis, cell invasion, local immune system functions and extracellular matrix formation [78,79].…”

Section: Growth Factorsmentioning

confidence: 99%